Printable version of editorial staff

Dr. Roukos: Invited/Solicited/Commissioned Articles EDITORIALS/REVIEWS/COMMENTARIES/CRITIQUES ONLY: Overall Impact Factor 45.869 Impact Factor 1. Roukos DH. Biologic genetic information predicts and may change future clinical outcomes in both at-risk hereditary cancer individuals and metastatic recurrence cancer patients Cancer Biol Ther (in press). (Invited review). 2.981       2. Roukos DH, Fatouros M, Tsianos E, Kappas AM. Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification? Nat Clin Pract Oncol (in press). (Invited commentary). -       3. Roukos DH and Kappas AM. Prevention of hereditary breast ovarian cancer. Individualized approaches Nat Clin Pract Oncol (In press). (Invited Review). - (new)       4.  Roukos DH, Liakakos T, Karatzas G, Kappas AM.  Can VEGF-D and VEGFR-3 be used as biomarkers for  therapeutic  decisions in patients with gastric cancer?  Nat Clin Pract Oncol. 2006 Aug;3(8):418-9. (Invited  Commentary) - (new) - 5.  Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P,  Roukos DH,  Kappas AM.  Selecting a specific pre- or postoperative adjuvant therapy  for individual patients with operable gastric  cancer.  Expert Rev Anticancer Ther 2006 June; 6(6): 931-9.  (Invited Review) - (new) - 6.  Roukos DH, Fatouros M, Paraskevaidis E, Kappas AM.  Is an aromatase inhibitor more effective than tamoxifen in  neoadjuvant endocrine therapy for breast cancer?  Nat Clin Pract Oncol. 2006 Feb; 3(2): 82-83. (Invited  Commentary) - (new) - 7.  Roukos DH, Kappas AM.  Does neoadjuvant versus adjuvant systemic treatment improve  outcomes in breast cancer?  Nat Clin Pract Oncol 2005 Jul 01; 2: 342-343. (Invited  commentary) - (new )       8.  Roukos DH, Kappas AM.  Perspectives in the treatment of gastric cancer.  Nat Clin Pract Oncol 2005 Feb 01; 2:98-107 (Invited Review) - (new )       9.    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A,  Paraskevaidis E, Kappas AM.  Factors increasing local recurrence in breast conserving  surgery.  Expert Rev Anticancer Ther 2005 Aug; 5(4): 737-45  (Invited Review) -       10.    Agnantis NJ, Paraskevaidis E, Roukos DH.  Preventing breast, ovarian cancer in BRCA carriers: rational of  prophylactic surgery and promises of surveillance.  Ann Surg Oncol. 2004 Dec;11(12):1030-4. Epub 2004 Nov 15.  (Editorial). 4.035       11.    Kappas AM, Fatouros M , Roukos DH .  Is it time to change surgical strategy for gastric cancer in the  United States?  Ann Surg Oncol. 2004 Aug;11(8):727-30. Epub 2004 Jul 12  (Editorial). 4.035       12.  Roukos DH  Early-stage gastric cancer: a highly treatable disease.  Ann Surg Oncol. 2004 Feb;11(2):127-9 (Editorial). 4.035       13.  Roukos DH , Kappas AM , Agnantis NJ .  Perspectives and risks of breast-conservation therapy for breast  cancer.  Ann Surg Oncol. 2003 Aug;10(7):718-21 (Editorial). 3.574       14.  Roukos DH , Agnanti NJ , Paraskevaidis E, Kappas AM.  Approaching the dilemma between prophylactic bilateral  mastectomy  or oophorectomy for breast and ovarian cancer  prevention in carriers of BRCA1 or BRCA2 mutations.  Ann Surg Oncol. 2002 Dec;9(10):941-3 (Editorial). 3.824       15.  Kappas AM , Roukos DH.  Quality of surgery determinant for the outcome of patient with  gastric cancer.  Ann Surg Oncol. 2002 Nov;9(9):828-30 (Editorial). 3.824       16.  Roukos DH, Kappas AM .  Targeting the optimal extent of lymph node dissection for gastric  cancer.  J Surg Oncol. 2002 Oct;81(2):59-62; discussion 62 (Guest  Editorial). 1.502       17.  Roukos DH , Kappas AM , Tsianos E .  Role of surgery in the prophylaxis of hereditary cancer  syndromes.  Ann Surg Oncol. 2002 Aug;9(7):607-9 (Editorial). 3.824       18.  Roukos DH  Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to  extensive surgery?  Ann Surg Oncol. www.replicadealer.net 2002 Apr;9(3):220-1 (Editorial). 3.824       19.  Roukos DH, Kappas AM .  Limitations in controlling risk for recurrence after curative surgery  for advanced gastric cancer are now well-explained by molecular- based mechanisms.  Ann Surg Oncol. 2001 Sep;8(8):620-1 (Editorial). 3.308       20.  Roukos DH .  Current status and future perspectives in gastric cancer  management.  Cancer Treat Rev. 2000 Aug;26(4):243-55 (Invited Review). 2.053       21.  Roukos DH.  Extended (D2) lymph node dissection for gastric cancer: do  patients benefit?  Ann Surg Oncol. 2000 May;7(4):253-5. 2.8       22.  Roukos DH , Kappas AM, Encke A .  Extensive lymph-node dissection in gastric cancer: is it of  therapeutic value?  Cancer Treat Rev. 1996 Jul;22(4):247-52 (Editorial). 2.250 Dr. Roukos INVITED ARTICLES:                   Overall Impact Factor 45.869

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655